In the first half of 2013, Zentiva Romania had a turnover of RON160.9 million and a net profit of RON28.35 million.
The drug maker targets a growth of 8.4% in turnover this year, to RON348 million (EUR78.2 million), and a 18.6% growth in net profit, to RON47.8 million (EUR10.7 million).
Also in 2014, the former Sicomed factory in Bucharest plans to invest RON7 million in production facilities and equipment .
According to the latest available data, French group Sanofi-Aventis owns 81.6% of Zentiva Romania’s shares.
On the Romanian market, the French drug maker operates through two separate units: Sanofi-Aventis Romania and Zentiva Romania.
Sanofi Romania was the second largest pharmaceutical company in Romania in the first half of 2014, with a market share of 6.9% and sales of EUR183.4 million, overtaken by Roche, according to Cegedim data.
Zentiva last traded in Bucharest on August 5, at RON1.22 a share, up 0.91%.